Cargando…
Use of Sotrovimab for COVID-19 in a Patient with International Germ Cell Consensus Classification Poor Prognosis Testicular Germ Cell Tumor
A 35-year-old man was diagnosed with stage IIIC non-seminoma with paralysis of the lower half of his body due to 8th thoracic spine metastasis. The patient received bleomycin, etoposide, and cisplatin (BEP) therapy. On day 4 of the second course of BEP, the patient developed a fever and was diagnose...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601775/ https://www.ncbi.nlm.nih.gov/pubmed/37900855 http://dx.doi.org/10.1159/000533888 |
_version_ | 1785126262131392512 |
---|---|
author | Nagasaka, Hirotaka Takebe, Shinichi Yamamoto, Shotaro Kondo, Takuya Terao, Hideyuki Nakaigawa, Noboru Kishida, Takeshi |
author_facet | Nagasaka, Hirotaka Takebe, Shinichi Yamamoto, Shotaro Kondo, Takuya Terao, Hideyuki Nakaigawa, Noboru Kishida, Takeshi |
author_sort | Nagasaka, Hirotaka |
collection | PubMed |
description | A 35-year-old man was diagnosed with stage IIIC non-seminoma with paralysis of the lower half of his body due to 8th thoracic spine metastasis. The patient received bleomycin, etoposide, and cisplatin (BEP) therapy. On day 4 of the second course of BEP, the patient developed a fever and was diagnosed with coronavirus disease (COVID-19). COVID-19 was suspected to worsen because of cancer and chemotherapy-induced immunosuppression. However, the benefits of continuing BEP therapy outweighed these risks. After obtaining fully informed consent, BEP therapy was continued from day 5, while sotrovimab (anti-COVID-19 drug) was administered. The second course of BEP was completed without worsening severe COVID-19 or bleomycin-induced lung injury. The patient completed four courses of BEP, with normalization of tumor markers, partial response on imaging, and improvement in lower body paralysis. In this case, we successfully treated a patient with testicular germ cell tumor with chemotherapy while having COVID-19 without treatment delay. During the COVID-19 pandemic, concomitant chemotherapy and COVID-19 treatment are warranted because delaying treatment will decrease the efficacy of highly curative diseases such as germ cell tumors. |
format | Online Article Text |
id | pubmed-10601775 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-106017752023-10-27 Use of Sotrovimab for COVID-19 in a Patient with International Germ Cell Consensus Classification Poor Prognosis Testicular Germ Cell Tumor Nagasaka, Hirotaka Takebe, Shinichi Yamamoto, Shotaro Kondo, Takuya Terao, Hideyuki Nakaigawa, Noboru Kishida, Takeshi Case Rep Oncol Case Report A 35-year-old man was diagnosed with stage IIIC non-seminoma with paralysis of the lower half of his body due to 8th thoracic spine metastasis. The patient received bleomycin, etoposide, and cisplatin (BEP) therapy. On day 4 of the second course of BEP, the patient developed a fever and was diagnosed with coronavirus disease (COVID-19). COVID-19 was suspected to worsen because of cancer and chemotherapy-induced immunosuppression. However, the benefits of continuing BEP therapy outweighed these risks. After obtaining fully informed consent, BEP therapy was continued from day 5, while sotrovimab (anti-COVID-19 drug) was administered. The second course of BEP was completed without worsening severe COVID-19 or bleomycin-induced lung injury. The patient completed four courses of BEP, with normalization of tumor markers, partial response on imaging, and improvement in lower body paralysis. In this case, we successfully treated a patient with testicular germ cell tumor with chemotherapy while having COVID-19 without treatment delay. During the COVID-19 pandemic, concomitant chemotherapy and COVID-19 treatment are warranted because delaying treatment will decrease the efficacy of highly curative diseases such as germ cell tumors. S. Karger AG 2023-09-25 /pmc/articles/PMC10601775/ /pubmed/37900855 http://dx.doi.org/10.1159/000533888 Text en © 2023 The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Case Report Nagasaka, Hirotaka Takebe, Shinichi Yamamoto, Shotaro Kondo, Takuya Terao, Hideyuki Nakaigawa, Noboru Kishida, Takeshi Use of Sotrovimab for COVID-19 in a Patient with International Germ Cell Consensus Classification Poor Prognosis Testicular Germ Cell Tumor |
title | Use of Sotrovimab for COVID-19 in a Patient with International Germ Cell Consensus Classification Poor Prognosis Testicular Germ Cell Tumor |
title_full | Use of Sotrovimab for COVID-19 in a Patient with International Germ Cell Consensus Classification Poor Prognosis Testicular Germ Cell Tumor |
title_fullStr | Use of Sotrovimab for COVID-19 in a Patient with International Germ Cell Consensus Classification Poor Prognosis Testicular Germ Cell Tumor |
title_full_unstemmed | Use of Sotrovimab for COVID-19 in a Patient with International Germ Cell Consensus Classification Poor Prognosis Testicular Germ Cell Tumor |
title_short | Use of Sotrovimab for COVID-19 in a Patient with International Germ Cell Consensus Classification Poor Prognosis Testicular Germ Cell Tumor |
title_sort | use of sotrovimab for covid-19 in a patient with international germ cell consensus classification poor prognosis testicular germ cell tumor |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601775/ https://www.ncbi.nlm.nih.gov/pubmed/37900855 http://dx.doi.org/10.1159/000533888 |
work_keys_str_mv | AT nagasakahirotaka useofsotrovimabforcovid19inapatientwithinternationalgermcellconsensusclassificationpoorprognosistesticulargermcelltumor AT takebeshinichi useofsotrovimabforcovid19inapatientwithinternationalgermcellconsensusclassificationpoorprognosistesticulargermcelltumor AT yamamotoshotaro useofsotrovimabforcovid19inapatientwithinternationalgermcellconsensusclassificationpoorprognosistesticulargermcelltumor AT kondotakuya useofsotrovimabforcovid19inapatientwithinternationalgermcellconsensusclassificationpoorprognosistesticulargermcelltumor AT teraohideyuki useofsotrovimabforcovid19inapatientwithinternationalgermcellconsensusclassificationpoorprognosistesticulargermcelltumor AT nakaigawanoboru useofsotrovimabforcovid19inapatientwithinternationalgermcellconsensusclassificationpoorprognosistesticulargermcelltumor AT kishidatakeshi useofsotrovimabforcovid19inapatientwithinternationalgermcellconsensusclassificationpoorprognosistesticulargermcelltumor |